Edoxaban for Venous Thromboembolism Treatment—The New Kid on The Block for Latin America. A Practical Guide-Reference-Cited by-同舟云学术

Edoxaban for Venous Thromboembolism Treatment—The New Kid on The Block for Latin America. A Practical Guide

Published:2018-11-28 Issue:9_suppl Volume:24 Page:340S-349S
ISSN:1076-0296
Container-title:Clinical and Applied Thrombosis/Hemostasis
language:en
Short-container-title:Clin Appl Thromb Hemost

Author:

Ramacciotti Eduardo¹²³,Aguiar Valéria Cristina Resende²,Júnior Valter Castelli¹,Casella Ivan Benaducce⁴,Zerati Antonio Eduardo⁴^ORCID,Fareed Jawed³

Affiliation:

1. Vascular Surgery, Santa Casa de Sao Paulo School of Medical Sciences, São Paulo, Brazil

2. Vascular Surgery, Hospital e Maternidade Dr. Christóvão da Gama, Santo André, São Paulo, Brazil

3. Hemostasis & Thrombosis Research Laboratories at Loyola University Medical Center, Maywood, IL, USA

4. Vascular Surgery, Faculty of Medicine, University of São Paulo, São Paulo, Brazil

Abstract

Edoxaban, a direct factor Xa inhibitor (FXa), is the fourth direct oral anticoagulant (DOAC) approved for clinical use in the treatment of venous thromboembolism (VTE) in Latin America, following global approvals for this indication. Edoxaban features some particular characteristics when compared to the previously approved DOACs. This review summarizes the main properties of edoxaban, the outcomes results of its pivotal global clinical trials and the peculiar clinical features of this compound. This practical guide aims to help Latin America clinicians understand edoxaban, its proper indication and its use for the appropriate patients with VTE.

Publisher

SAGE Publications

Subject

Hematology,General Medicine

Link

http://journals.sagepub.com/doi/pdf/10.1177/1076029618812955

Reference33 articles.

1. Predictors of Recurrence After Deep Vein Thrombosis and Pulmonary Embolism

2. Venous thromboembolism in Latin America: a review and guide to diagnosis and treatment for primary care

3. The diagnosis and treatment of venous thromboembolism

4. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis

5. A Comprehensive Overview of Direct Oral Anticoagulants for the Management of Venous Thromboembolism

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bridging the Gap in Cancer-Related Stroke Management: Update on Therapeutic and Preventive Approaches;International Journal of Molecular Sciences;2023-04-28

2. An Update in Anticoagulant Therapy for Patients with Cancer-Associated Venous Thromboembolism;Current Oncology Reports;2023-03-16

3. Direct Oral Anticoagulants for the Treatment of Cancer-Associated Venous Thromboembolism: A Latin American Perspective;Clinical and Applied Thrombosis/Hemostasis;2022-01

4. Cost-effectiveness of edoxaban vs low-molecular-weight heparin and warfarin for cancer-associated thrombosis in Brazil;Thrombosis Research;2020-12